Sox2 expression involvement in the oncogenicity and radiochemoresistance of oral cancer stem cells

Oral Oncology

Volumn 51, Issue 1, 2015, Pages 31-39

  Chou, Ming Yung ^a,b   Hu, Fang Wei ^a,b   Yu, Chuan Hang ^a,b   Yu, Cheng Chia ^a,b  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Cancer stem cells; EMT; Oral squamous cell carcinoma (OSCC); Radiochemoresistance; Sox2

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; CISPLATIN; HERMES ANTIGEN; TRANSCRIPTION FACTOR SOX2; ANTINEOPLASTIC AGENTS; DNA PRIMERS; SOX2 PROTEIN, HUMAN; SOXB1 TRANSCRIPTION FACTORS;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENICITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; PROTEIN EXPRESSION; RADIOSENSITIVITY; SPHEROID CELL; SURVIVAL RATE; TUMOR INVASION; XENOTRANSPLANTATION; ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; DRUG EFFECTS; DRUG RESISTANCE, NEOPLASM; HUMANS; METABOLISM; MICE; MICE, NUDE; MOUTH NEOPLASMS; NEOPLASTIC STEM CELLS; PATHOLOGY; RADIATION EFFECTS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CELL LINE, TUMOR; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; HUMANS; MICE; MICE, NUDE; MOUTH NEOPLASMS; NEOPLASTIC STEM CELLS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SOXB1 TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920516848     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2014.10.002     Document Type: Article

References (48)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Yu CC, Tsai LL, Wang ML, Yu CH, Lo WL, Chang YC, et al. MiR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer. Cancer Res 2013;73:3425-40.
3. Lim YC, Kang HJ, Moon JH. C-Met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell. Oral Oncol 2014;50:633-9.
4. Graham V, Khudyakov J, Ellis P, Pevny L. SOX2 functions to maintain neural progenitor identity. Neuron 2003;39:749-65.
5. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-72.
6. Herreros-Villanueva M, Zhang JS, Koenig A, Abel EV, Smyrk TC, Bamlet WR, et al. SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells. Oncogenesis 2013;2:e61.
7. Ji J, Zheng PS. Expression of Sox2 in human cervical carcinogenesis. Hum Pathol 2010;41:1438-47.
8. Piva M, Domenici G, Iriondo O, Rabano M, Simoes BM, Comaills V, et al. Sox2 promotes tamoxifen resistance in breast cancer cells. EMBO Mole Med 2014;6:66-79.
9. Ye X, Wu F, Wu C, Wang P, Jung K, Gopal K, et al. Beta-Catenin, a Sox2 binding partner, regulates the DNA binding and transcriptional activity of Sox2 in breast cancer cells. Cell Signal 2014;26:492-501.
10. Stolzenburg S, Rots MG, Beltran AS, Rivenbark AG, Yuan X, Qian H, et al. Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Res 2012;40:6725-40.
11. Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Ioue Y, et al. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol 2009;16:3488-98.
12. Decarvalho AC, Nelson K, Lemke N, Lehman NL, Arbab AS, Kalkanis S, et al. Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo. Stem Cells 2010;28:181-90.
13. Sutter R, Shakhova O, Bhagat H, Behesti H, Sutter C, Penkar S, et al. Cerebellar stem cells act as medulloblastoma-initiating cells in a mouse model and a neural stem cell signature characterizes a subset of human medulloblastomas. Oncogene 2010;29:1845-56.
14. Okumura K, Konishi A, Tanaka M, Kanazawa M, Kogawa K, Niitsu Y. Establishment of high- and low-invasion clones derived for a human tongue squamous-cell carcinoma cell line SAS. J Cancer Res Clin Oncol 1996;122:243-8.
15. Rangan SR. A new human cell line (FaDu) from a hypopharyngeal carcinoma. Cancer 1972;29:117-21.
16. Shieh TM, Lin SC, Liu CJ, Chang SS, Ku TH, Chang KW. Association of expression aberrances and genetic polymorphisms of lysyl oxidase with areca-associated oral tumorigenesis. Clinical Cancer Res: Offic J Am Assoc Cancer Res 2007;13:4378-85.
17. Lin CW, Chen PN, Chen MK, Yang WE, Tang CH, Yang SF, et al. Kaempferol reduces matrix metalloproteinase-2 expression by down-regulating ERK1/2 and the activator protein-1 signaling pathways in oral cancer cells. PLoS ONE 2013;8:e80883.
18. Yu FS, Yang JS, Yu CS, Lu CC, Chiang JH, Lin CW, et al. Safrole induces apoptosis in human oral cancer HSC-3 cells. J Dent Res 2011;90:168-74.
19. Lin SC, Liu CJ, Chiu CP, Chang SM, Lu SY, Chen YJ. Establishment of OC3 oral carcinoma cell line and identification of NF-kappa B activation responses to areca nut extract. J Oral Pathol & Med: Official Public Int Assoc Oral Patholog Am Acad Oral Pathol 2004;33:79-86.
20. Chen HM, Liu CM, Yang H, Chou HY, Chiang CP, Kuo MY. 5-Aminolevulinic acid induce apoptosis via NF-kappaB/JNK pathway in human oral cancer Ca9-22 cells. J Oral Pathol Med: Offic Public Int Assoc Oral Pathol Am Acad Oral Pathol 2011;40:483-9.
21. Lee SS, Tsai CH, Ho YC, Chang YC. The upregulation of heat shock protein 70 expression in areca quid chewing-associated oral squamous cell carcinomas. Oral Oncol 2008;44:884-90.
22. Srisopark SS. Phagocytosis of thorotrast by human gingival epithelial (SG line) cells in tissue culture: an electron microscopic study. J Dent Assoc Thailand 1975;25:77-102.
23. Chen YS, Wu MJ, Huang CY, Lin SC, Chuang TH, Yu CC, et al. CD133/Src axis mediates tumor initiating property and epithelial-mesenchymal transition of head and neck cancer. PLoS ONE 2011;6:e28053.
24. Lo JF, Yu CC, Chiou SH, Huang CY, Jan CI, Lin SC, et al. The epithelial-mesenchymal transition mediator S100A4 maintains cancer-initiating cells in head and neck cancers. Cancer Res 2011;71:1912-23.
25. Wu MJ, Jan CI, Tsay YG, Yu YH, Huang CY, Lin SC, et al. Elimination of head and neck cancer initiating cells through targeting glucose regulated protein78 signaling. Mole Cancer 2010;9:283.
26. Wang XQ, Ongkeko WM, Chen L, Yang ZF, Lu P, Chen KK, et al. Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology 2010;52:528-39.
27. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med 2009;15:1010-2.
28. Hu FW, Tsai LL, Yu CH, Chen PN, Chou MY, Yu CC. Impairment of tumorinitiating stem-like property and reversal of epithelial-mesenchymal transdifferentiation in head and neck cancer by resveratrol treatment. Mol Nutr Food Res 2012;56:1247-58.
29. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008;451:141-6.
30. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-76.
31. Ferri AL, Cavallaro M, Braida D, Di Cristofano A, Canta A, Vezzani A, et al. Sox2 deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain. Development 2004;131:3805-19.
32. Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R. Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev 2003;17:126-40.
33. McCaughan F, Pole JC, Bankier AT, Konfortov BA, Carroll B, Falzon M, et al. Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung cancer. Am J Respir Crit Care Med 2010;182:83-91.
34. Chen Y, Shi L, Zhang L, Li R, Liang J, Yu W, et al. The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem 2008;283:17969-78.
35. Neumann J, Bahr F, Horst D, Kriegl L, Engel J, Luque RM, et al. SOX2 expression correlates with lymph-node metastases and distant spread in right-sided colon cancer. BMC Cancer 2011;11:518.
36. Laga AC, Zhan Q, Weishaupt C, Ma J, Frank MH, Murphy GF. SOX2 and nestin expression in human melanoma: an immunohistochemical and experimental study. Exp Dermatol 2011;20:339-45.
37. Annovazzi L, Mellai M, Caldera V, Valente G, Schiffer D. SOX2 expression and amplification in gliomas and glioma cell lines. Cancer Genomics Proteomics 2011;8:139-47.
38. Zhang J, Chang DY, Mercado-Uribe I, Liu J. Sex-determining region Y-box 2 expression predicts poor prognosis in human ovarian carcinoma. Hum Pathol 2012;43:1405-12.
39. Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga K, et al. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene 2012;31:1354-65.
40. Basu-Roy U, Seo E, Ramanathapuram L, Rapp TB, Perry JA, Orkin SH, et al. Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas. Oncogene 2012;31:2270-82.
41. Boumahdi S, Driessens G, Lapouge G, Rorive S, Nassar D, Le Mercier M, et al. SOX2 controls tumour initiation and cancer stem-cell functions in squamouscell carcinoma. Nature 2014.
42. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003;112:1776-84.
43. Lo WL, Yu CC, Chiou GY, Chen YW, Huang PI, Chien CS, et al. MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck squamous cell carcinoma stem cells. J Pathol 2011;223:482-95.
44. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15.
45. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 2008;3:e2888.
46. Jeon HM, Sohn YW, Oh SY, Kim SH, Beck S, Kim S, et al. ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9∗-mediated suppression of SOX2. Cancer Res 2011;71:3410-21.
47. Otsubo T, Akiyama Y, Hashimoto Y, Shimada S, Goto K, Yuasa Y. MicroRNA-126 inhibits SOX2 expression and contributes to gastric carcinogenesis. PLoS ONE 2011;6:e16617.
48. Bourguignon LY, Wong G, Earle C, Chen L. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to selfrenewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem 2012;287:32800-24.